

ABSTRACT

A study on “COMPARISON OF THE EFFICACY AND SAFETY OF SINGLE DOSE OF 4mg Vs 2mg INTRAVITREAL TRIAMCINOLONE ACETONIDE INJECTION FOR DIABETIC CYSTOID MACULAR EDEMA”

AIM OF THE STUDY

To Prospectively Compare the Efficacy of 4mg Vs 2mg Intravitreal Triamcinolone Acetonide Injection for Diabetic Cystoid Macular Edema

PRIMARY OBJECTIVE

To determine the dose with superior visual outcome

SECONDARY OBJECTIVE

To determine the dose with less complications with equivocal clinical benefits

STUDY DESIGN

Prospective Comparative Interventional study

METHODOLOGY:

50 patients with diabetic cystoid macular edema were selected and divided into two groups of 25 each. First group was treated with 4mg IVTA and

second group was treated with 2 mg IVTA. All the patients were followed up with visual acuity assessment, central macular thickness assessment and intraocular pressure measurement at 4, 12 and 24 weeks. Results of both the groups were compared.

CONCLUSIONS:

- Visual improvement is noted with both 4 mg and 2 mg Intravitreal Triamcinolone Acetonide though it is more pronounced and sustained with 4 mg dosage compared with 2 mg dosage

Both 4 mg and 2 mg Intravitreal Triamcinolone Acetonide are well tolerated over 6 month period with significant safety. But 4 mg dosage is associated with mild elevation of intraocular pressure in some patients unlike 2 mg dosage which appears to be more safer.

KEY WORDS:

DIABETIC MACULAR EDEMA

CYSTOID MACULAR EDEMA

INTRAVITREAL TRIAMCINOLONE ACETONIDE

CENTRAL MACULAR THICKNESS